Uro Today reports well known physician Dr. Joseph G. Jurcic, after reviewing the early treatment of acute myelogenous leukemia (AML) with Bi213-Lintuzumab when contrasted with beta-emitters I132 and Y90, found the alpha therapy was far superior in absorbed dose to the marrow compared to whole body doses.

He also reviewed results from a Phase I trial where patients received Ac225-Lintuzumab. The physician summarized that a clear rational for using A225-Lintuzumab for treatment of AML and probably in other hematologic malignancies like MDS and Myeloma.

Dr. Joseph Jurcic is Professor of Medicine at Columbia University Medical Center and Director of the Hematologic Malignancies Section of the Division of Hematology/Oncology. His main focus is the treatment of acute and chronic leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome. Research interests include acute myeloid leukemia, radioimmunotherapy with alpha and beta particle-emitting radioisotopes, monoclonal antibody therapy for leukemia, the development of novel small molecule inhibitors for leukemia, and the molecular monitoring of minimal residual disease.

He is the 2001 recipient of the Louis and Allston Boyer Young Investigator Award for Distinguished Achievement in Biomedical Research from Memorial Sloan-Kettering Cancer Center. Dr. Jurcic authored or coauthored of more than 80 articles and book chapters, has been the principal investigator on over 25 clinical trials, and regularly lectures at national and international meetings. He serves as a Leukemia Section Editor for The Oncologist. Prior to joining the faculty at Columbia University Medical Center, he was an Attending Physician on the Leukemia Service at Memorial Sloan-Kettering Cancer Center for over 18 years.

Source: Urotoday

Pin It on Pinterest